S. Stafford

Tumor infiltrating lymphocytes expanded from pediatric neuroblastoma display heterogeneity of phenotype and function

Jolien Wolbert, John Anderson, G. Barone, 2019, PloS one.

A phase I study of oral ZD 1839 given daily in patients with solid tumors: IND.122, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group

L. Seymour, H. Hirte, W. Miller, 2005, Investigational New Drugs.

Antitumor activity without on-target off-tumor toxicity of GD2–chimeric antigen receptor T cells in patients with neuroblastoma

K. McHugh, I. Dragoni, A. Akarca, 2020, Science Translational Medicine.

Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells

Adrian J. Thrasher, Waseem Qasim, Stuart Adams, 2017, Science Translational Medicine.

First Clinical Application of Talen Engineered Universal CAR19 T Cells in B-ALL

K. Peggs, P. Veys, S. Samarasinghe, 2015 .

Time to Switch to Second-line Antiretroviral Therapy in Children With Human Immunodeficiency Virus in Europe and Thailand

A. Trkola, P. Tovey, C. Königs, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

An NCIC CTG phase I/pharmacokinetic study of the matrix metalloproteinase and angiogenesis inhibitor BAY 12-9566 in combination with 5-fluorouracil/leucovorin

L. Seymour, W. Walsh, C. Lathia, 2004, Investigational New Drugs.

An NCIC-CTG phase I dose escalation pharmacokinetic study of the matrix metalloproteinase inhibitor BAY 12-9566 in combination with doxorubicin

B. Schwartz, C. Lathia, D. Stewart, 2005, Investigational New Drugs.